SEATTLE, Sept. 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the 14-Day version of the Carnation Ambulatory Monitor (“CAM™”), the industry’s only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia […]
Rhythm
iRhythm Announces Collaboration with Verily to Develop Health Management Solutions for Atrial Fibrillation Patients
SAN FRANCISCO, Sept. 04, 2019 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC) today announced a collaboration with Verily, an Alphabet company, focused on the development of solutions aimed at improving the screening, diagnosis and management of patients with atrial fibrillation (AFib). This collaboration brings together iRhythm’s expertise in AI based arrhythmia […]
Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension
Late-breaking BackBeat CNT™ randomized, double-blind clinical results selected by Cardiovascular Research Foundation for presentation at TCT 2019 NEW HOPE, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) — Orchestra BioMed™, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, announced today […]
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation
– ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement – Data contributes to growing body of evidence supporting edoxaban in combination […]
Biosense Webster, Inc. Announces Catheter Ablation May Be up to 10 Times More Effective Than Standard Drug Therapy Alone at Delaying Progression of Atrial Fibrillation
PARIS–(BUSINESS WIRE)–Results from The Atrial Fibrillation Progression Trial (ATTEST), were presented on August 31st at the ESC* Congress 2019 in Paris, France. ATTEST is the first randomised controlled trial to directly compare the effectiveness of ablation using radiofrequency (RF) catheters versus standard antiarrhythmic drugs (AAD) in delaying atrial fibrillation (AF) progression. The […]
Impella® SmartAssist Platform Launches at ESC, Designed to Further Improve Patient Outcomes
The new Impella CP heart pump features a fiber optic sensor, optimally positioned to measure the placement signal in the aorta, identify pump placement and enable repositioning without the use of imaging. (Graphic: Abiomed) PARIS–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces today that the Impella CP® with SmartAssist technology, which is designed to improve patient […]
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
10 years ago, RE-LY® marked the first time a randomised trial showed that a non-vitamin K antagonist oral anticoagulant (NOAC) was safer and at least as effective as warfarin for stroke prevention in atrial fibrillation (SPAF)1-3 First major scientific advancement in anticoagulation care in over fifty years Over 100,000 patients have […]
LindaCare Partners with Philips
LindaCare’s OnePulse combines with Philips’ IntelliSpace Cardiovascular informatics platform to streamline in-hospital and remote follow-up care for patients with cardiac implantable electronic devices LEUVEN, Belgium and STAMFORD, Conn., Aug. 29, 2019 /PRNewswire/ — Prior to the European Society of Cardiology (ESC) Congress 2019 (Paris, France, August 31 – September 4), LindaCare announced that it is collaborating with Philips to combine LindaCare’s innovative […]
Samsung Collaboration with Kaiser Permanente Delivers Improvements in Home-Based Cardiac Rehabilitation
The home-based cardiac rehabilitation program experienced just 2 percent readmission rates and saw a 74 percent improvement in completion rates compared to clinic-based programs Samsung Electronics revealed the results of a joint cardiac rehabilitation initiative, developed in collaboration with Kaiser Permanente, the largest not-for-profit integrated health system in America. Samsung […]
EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO
SUNNYVALE, Calif., Aug. 27, 2019 /PRNewswire/ — EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of its pivotal SOLVE CRT clinical trial and to prepare for commercialization of the WiSE Cardiac Resynchronization Therapy (CRT) System. This […]



